Table 1. Clinical characteristics of lung cancer patients.
| Characteristics | Stratification | n (%) |
|---|---|---|
| Total number of patients | 467 (100) | |
| Median age (range) | 57 (20–80) | |
| <57 | 234 (50.1) | |
| ≥57 | 233 (49.9) | |
| Sex | Male | 371 (79.4) |
| Female | 96 (20.6) | |
| History of smoking | Yes | 286 (61.2) |
| No | 181 (38.8) | |
| Histological type | NSCLC | 371 (79.4) |
| SCLC | 68 (14.6) | |
| Othera | 28 (6.0) | |
| NSCLC | SCC | 167 (35.8) |
| ADC | 204 (43.7) | |
| Stage (NSCLC) | Early stage (I, II) | 13 (2.8) |
| Advanced stage (III, IV) | 394 (84.4) | |
| Stage (SCLC) | Limited stage | 34 (7.3) |
| Extensive stage | 26 (5.6) | |
| Chemotherapy regimen | GP | 192 (41.1) |
| EP | 68 (14.6) | |
| PP | 137 (29.3) | |
| TP | 27 (5.8) | |
| DP | 29 (6.2) | |
| Otherb | 14 (3.0) | |
| Overall toxicity | Grade 0–2 | 286 (61.2) |
| Grade 3–4 | 181 (38.8) | |
| Performance score (PS) | 0 | 42 (9.0) |
| 1 | 395 (84.6) | |
| 2 | 30 (6.4) | |
| Gastrointestinal toxicity | Grade 0–2 | 366 (78.4) |
| Grade 3–4 | 101 (21.6) | |
| Hematologic toxicity | Grade 0–2 | 353 (75.6) |
| Grade 3–4 | 114 (24.4) |
Abbreviations: NSCLC, non-small-cell lung cancer; SCC, squamous-cell carcinoma; ADC, adenocarcinoma; SCLC, small-cell lung cancer; Othera, mixed-cell or undifferentiated carcinoma; GP, platinum+gemcitabine; EP, platinum+etoposide; PP, platinum+pemetrexed; TP, platinum+paclitaxel; DP, platinum+docetaxel; Otherb, platinum+irinotecan or platinum+ navelbine; n, number.